Roche said it is discontinuing two Huntington’s disease development programs after separate efficacy and safety readouts. In a letter to the patient community, Roche stated that tominersen (licensed via Ionis) did not meet its efficacy objective in a Phase 2 trial, despite target engagement. Roche also stopped RG6496, halting the early-stage study after animal data indicated the drug could not be given chronically with repeated dosing. Roche said both decisions were data-driven and pledged to present follow-up information after continued analysis. The company clarified that its Phase 1/2 Huntington’s gene therapy candidate RG6662 remains ongoing, keeping one program alive for families awaiting new options.